Active substance
Results for the substance alpelisib
3 results
About this active substance
Alpelisib is a medication used in the treatment of advanced or metastatic breast cancer, particularly in patients with PIK3CA gene mutations. It is a PI3K kinase inhibitor, an enzyme involved in the growth and survival of cancer cells. By blocking this enzyme, alpelisib slows cancer progression and may reduce tumor size.
Alpelisib is taken orally, usually once daily, in combination with other medications such as fulvestrant. The treatment is primarily indicated for postmenopausal women and men with HR-positive, HER2-negative breast cancer.
Side effects may include hyperglycemia, nausea, diarrhea, fatigue, and skin rashes. In rare cases, severe reactions such as pneumonitis or kidney impairment may occur.
Patients should be regularly monitored for blood sugar levels and other potential adverse reactions. It is essential to strictly follow the doctor's recommendations to optimize treatment benefits and minimize risks. Alpelisib is an important option for patients with advanced breast cancer, offering a chance to control the disease.
Alpelisib is taken orally, usually once daily, in combination with other medications such as fulvestrant. The treatment is primarily indicated for postmenopausal women and men with HR-positive, HER2-negative breast cancer.
Side effects may include hyperglycemia, nausea, diarrhea, fatigue, and skin rashes. In rare cases, severe reactions such as pneumonitis or kidney impairment may occur.
Patients should be regularly monitored for blood sugar levels and other potential adverse reactions. It is essential to strictly follow the doctor's recommendations to optimize treatment benefits and minimize risks. Alpelisib is an important option for patients with advanced breast cancer, offering a chance to control the disease.
-
-
PIQRAY 200mg film-coated tablets EUROPHARM ORIGINAL MEDICINE
-
PIQRAY 50mg+200mg 50mg. 200mg film-coated tablets EUROPHARM ORIGINAL MEDICINE